Cancer Immunotherapy 102 (2023 AMW) Session
2023 AAO-HNSF Annual Meeting & OTO Experience
PROGRAM DESCRIPTION: This is the second part of the popular course, previously named Immunotherapy for Cancer: What the Otolaryngologist needs to Know. In recent years immunotherapy has shown promise as a new therapeutic pathway for the treatment of head and neck cancer. The second part of this course will focus on emerging biomarkers in oncology, ongoing clinical trials and exciting future directions for the field. Understanding the current state and future directions of immunotherapy is valuable for counseling patients. This panel, geared toward general otolaryngologist, head and neck surgeons and trainees, will provide an in-depth review of biomarkers, ongoing clinical trials, and potential future agents.OUTCOME OBJECTIVE 1: Upon completion of this activity, the participants should have an understanding of new and emerging biomarkers for HNC.OUTCOME OBJECTIVE 2: Upon completion of this activity, the participants should have an understanding of ongoing clinical trials evaluating immunotherapies for treatment of HNC.OUTCOME OBJECTIVE 3: Upon completion of this activity, the participants should have an understanding of new and emerging immunotherapies for HNC.BACKGROUND STATEMENT: The field of immunotherapy is evolving rapidly. The general otolaryngologist and sub-specialist are getting inquiries from patients regarding these therapies. Staying up-to-date on the current as well as future therapies is imperative.